NASDAQ:MKD Molecular Data (MKD) Stock Price, News & Analysis → Now Open: Crypto emergency update (From InvestorPlace) (Ad) Free MKD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.40▼$0.7152-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Molecular Data alerts: Email Address Ad InvestorPlaceYou’re invited: Biggest crypto event of 2024During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. About Molecular Data Stock (NASDAQ:MKD)Molecular Data Inc., through its subsidiaries, operates in the chemical e-commerce business in the People's Republic of China. The company operates technology-driven platform that connects participants along the chemical value chain through its integrated solutions. It delivers e-commerce solutions, financial solutions, warehousing and logistics solutions, and software-as-a-service suites for participants in the traditional chemical industry. The company offers its e-commerce solutions through online platform that consists of molbase.com and molbase.cn websites; Moku Data Weixin account; Chemical Community app; and other ancillary platforms. Molecular Data Inc. was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.Read More Ad InvestorPlaceYou’re invited: Biggest crypto event of 2024During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. MKD Stock News HeadlinesApril 16, 2024 | msn.comResearchers create new AI pipeline for identifying molecular interactionsApril 15, 2024 | msn.comDeveloping a machine learning model to explore DNA methylationApril 19, 2024 | InvestorPlace (Ad)You’re invited: Biggest crypto event of 2024During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.April 12, 2024 | marketwatch.comMolecular Templates to Cut 30% of Staff, Chief Medical OfficerApril 12, 2024 | msn.comResearchers shed light on the molecular causes of different functions of opioid receptorsApril 11, 2024 | msn.comSciY launches new BioDrive tool and registration module for enhanced data management and collaboration in molecular biology researchMarch 29, 2024 | msn.comAdvancing drug discovery with AI: Introducing the KEDD frameworkMarch 29, 2024 | msn.comGene editing technology reveals molecular mechanisms governing diatom population density signalsApril 19, 2024 | InvestorPlace (Ad)You’re invited: Biggest crypto event of 2024During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.March 27, 2024 | msn.comAdvancements in Molecular Memory Unlocking the Potential of Photoswitch MoleculesMarch 16, 2024 | markets.businessinsider.comMolecular Partners AG: Strong Financials & Promising Pipeline Justify Buy RatingMarch 14, 2024 | msn.comStudy identifies molecular alterations in brain tissue and blood of people who committed suicideFebruary 21, 2024 | msn.comNew findings on the link between myotonic dystrophy 2 and autoimmune diseasesFebruary 6, 2024 | msn.comStudy identifies molecular mechanisms of rare neurodevelopmental disorderFebruary 1, 2024 | msn.comHuman cells building 'molecular highways' captured for first timeJanuary 23, 2024 | msn.com4D Molecular gets FDA rare pediatric disease status for CF drugJanuary 14, 2024 | msn.comNew research provides a molecular look at the mechanisms behind pigmentation variationJanuary 9, 2024 | msn.comResearch better characterizes a rare form of leukemia on the molecular levelJanuary 2, 2024 | msn.comPreviously unidentified protein variant shields against Parkinson's diseaseNovember 13, 2023 | tmcnet.comBostonGene to Showcase AI-Driven Molecular Profiling Solutions at the Association for Molecular Pathology 2023 Annual MeetingOctober 10, 2023 | markets.businessinsider.comCENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic OfferingAugust 15, 2023 | msn.comMolecular communication: Experts are interpreting the language of lifeAugust 9, 2023 | lse.co.ukMolecular Enrgy Share ChatJuly 28, 2023 | investing.comMolecular Data Inc (MKDTY)July 7, 2023 | msn.com4D Molecular Therapeutics: A Complicated StoryJune 19, 2023 | benzinga.comMolecular Diagnostics Partnering Deals Report 2016-2023 - Undertake Due Diligence to Assess Suitability of Your Proposed Deal TermsJune 7, 2023 | seekingalpha.com4D Molecular stock rallies following promising data for CF therapySee More Headlines Receive MKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Data and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:MKD CUSIPN/A CIK1758736 Webwww.molbase.cn Phone86-21-5436-5166Fax86-40-0602-1666Employees189Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Steven Foo (Age 50)CEO & CFO Dr. Dongliang Chang (Age 47)Founder & Chairman of Board of Directors Mr. Jingming ZhongCompliance OfficerKey CompetitorsEqonexNASDAQ:EQOSFull Truck AllianceNYSE:YMMIntegrated Media TechnologyNASDAQ:IMTEOnion GlobalNYSE:OGBLYRenovare EnvironmentalNASDAQ:RENOView All Competitors MKD Stock Analysis - Frequently Asked Questions When did Molecular Data's stock split? Molecular Data's stock reverse split on Monday, May 23rd 2022. The 1-15 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Molecular Data IPO? Molecular Data (MKD) raised $69 million in an initial public offering (IPO) on the week of December 30th 2019. The company issued 11,500,000 shares at $5.00-$7.00 per share. AMTD, Fosun Hani and Boustead Securities acted as the underwriters for the IPO and Tiger Brokers and Guotai Junan International were co-managers. This page (NASDAQ:MKD) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceTop 5 AI Stocks to Buy for 2024Market Moving TrendsHow Biden has already won 2024Porter & CompanyOptions trading has suddenly become more reliable.Eagle PublishingTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Data Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.